Top Biotech Acquisition Candidates
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
Karen Andersen: I'm Karen Andersen, senior biotech analyst at Morningstar. With me today to discuss the M&A environment is biotech analyst Lauren Migliore. Thanks for joining me, Lauren.
Lauren Migliore: Good to be here, Karen.
Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.